NeuroNOS, a Boston, MA-based biopharmaceutical company focused on developing treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, raised $2M in funding.
Backers were not disclosed.
The company intends to use the funds to accelerate the preclinical development of its small-molecule drug, designed as an injectable or oral treatment for children with autism.
Led by CEO Amir Avniel, NeuroNOS is a biopharmaceutical company developing a novel drug for Autism Spectrum Disorder (ASD) and other neurological conditions. Its small-molecule therapy, based on technology from the Hebrew University, is designed for subcutaneous injection or oral administration and aims to regulate nitric oxide (NO) levels in the brain, a mechanism that has shown significant promise in preclinical studies. The company has demonstrated that balancing NO levels can lead to both behavioral and biological improvements in animal models of autism.
It is currently optimizing the drug’s delivery mechanism, with the first phase focusing on a subcutaneous (under-the-skin) injection to ensure optimal bioavailability and patient compliance.
FinSMEs
25/03/2025